CORRECTION Open Access



Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Rebecca A. Shatsky^{1,2}, Hemali Batra-Sharma^{1,2}, Teresa Helsten^{1,2}, Richard B. Schwab^{1,2}, Emily I. Pittman¹, Minya Pu¹, Elizabeth Weihe⁴, Emanuela M. Ghia^{1,5}, Laura Z. Rassenti^{1,5}, Alfredo Molinolo¹, Betty Cabrera⁶, James B. Breitmeyer⁷, George F. Widhopf Il^{2,5}, Karen Messer^{1,3}, Catriona Jamieson^{1,2,6,8}, Thomas J. Kipps^{1,5} and Barbara A. Parker^{1,2*}

Correction to: Shatsky et al. Breast Cancer Research (2024) 26:32https://doi.org/10.1186/s13058-024-01782-0

The original article contained three typesetting errors. "Her2-negative" in the title should have been written as "HER2-negative". Hence, the title should read: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer, as shown in this Correction Article.

In the Background section of the original article, on page 2, paragraph 2, there was a

The online version of the original article can be found at https://doi.org/10.1186/s13058-024-01782-0.

*Correspondence:

Barbara A. Parker

baparker@health.ucsd.edu

¹Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA 92093, USA

²Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA

³Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, San Diego, CA, USA

⁴Department of Radiology, University of California San Diego, La Jolla, San Diego, CA, USA

⁵Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA. USA

⁶University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA

⁷Oncternal Therapeutics, Inc., San Diego, CA, USA

⁸Sanford Stem Cell Institute, University of California San Diego, La Jolla, San Diego, CA, USA misspelling of "immuneodeficient". The correct spelling is "immunodeficient."

Also on page 2, in the section on Patient Selection, there was a misspelling of "HERer2". The correct spelling is "HER2-" as displayed throughout the manuscript.

The original article [1] has been updated.

Published online: 13 March 2024

References

 Shatsky RA, Batra-Sharma H, Helsten T, et al. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer. Breast Cancer Res. 2024;26:32. https://doi. org/10.1186/s13058-024-01782-0.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.